As of September 30, 2024, a total of 98 stem cell drugs in China have been approved to enter clinical trials with tacit consent (implied approval for clinical trials).

From January 1 to September 30, 2024, a total of 20 items were approved to acquiesce in clinical trials (implied approval for clinical trials), of which 17 items were derived from mesenchymal stem cells.

The specific information is as follows:

17 products derived from mesenchymal stem cells

3 sources of hematopoietic stem cells